Improved P50 Auditory Gating With Ondansetron in Medicated Schizophrenia Patients
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Most schizophrenia patients have a deficit in auditory sensory gating, which appears to be mediated by the alpha-7 nicotinic receptor, that is not improved with conventional antipsychotic treatment. This study examined the effects of ondansetron, a highly selective 5-HT3 antagonist, on the P50 auditory evoked potential. METHOD: Eight medicated outpatients with schizophrenia were given either ondansetron (16 mg) or placebo in a double-blind, placebo-controlled design. Evoked potentials were recorded at baseline and 1 hour, 2 hours, and 3 hours after receipt of drug. RESULTS: There was a highly significant improvement in P50 gating after ondansetron treatment. The maximal treatment difference was at 2 hours posttreatment (ondansetron: mean=41.4%, SD=39.7%; placebo: mean=80.2%, SD=21.3%). CONCLUSIONS: Ondansetron significantly enhanced P50 auditory gating in schizophrenia patients treated with typical antipsychotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report
Ziedonis, D., Hitsman, B., Beckham, J. C., Zvolensky, M., Adler, L. E., Audrain-McGovern, J., Breslau, N., Brown, R. A., George, T. P., Williams, J., et al. (2008) · Nicotine & Tobacco Research · doi:10.1080/14622200802443569 · Cited by 735
Self-citationMiyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Neurophysiological Endophenotypes of Schizophrenia: The Viability of Selected Candidate Measures
Turetsky, B. I., Calkins, M. E., Light, G. A., Olincy, A., Radant, A. D., & Swerdlow, N. R. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl060 · Cited by 567
Self-citationBraff, D. L., Freedman, R., Schork, N. J., & Gottesman, I. I. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl049 · Cited by 455
P50 sensory gating ratios in schizophrenics and controls: A review and data analysis
Patterson, J. V., Hetrick, W. P., Boutros, N. N., Jin, Y., Sandman, C., Stern, H., Potkin, S., & Bunney, W. E. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2007.02.009 · Cited by 352
Music therapy for people with schizophrenia and schizophrenia-like disorders
Geretsegger, M., Mössler, K. A., Bieleninik, Ł., Chen, X.-J., Heldal, T. O., & Gold, C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004025.pub4 · Cited by 348
Neurophysiological biomarkers for drug development in schizophrenia
Javitt, D. C., Spencer, K. M., Thaker, G. K., Winterer, G., & Hajós, M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2463 · Cited by 342
Review of Clinical Correlates of P50 Sensory Gating Abnormalities in Patients with Schizophrenia
Potter, D., Summerfelt, A., Gold, J., & Buchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj050 · Cited by 259
The 5-HT3receptor as a therapeutic target
Thompson, A. J., & Lummis, S. C. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.4.527 · Cited by 257
Schizophrenia and the α7 Nicotinic Acetylcholine Receptor
Martin, L. F., & Freedman, R. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78008-4 · Cited by 213
Levin, E. D., & Rezvani, A. H. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.019 · Cited by 129
“However, the 5HT3 actions of this drug may also underly its effectiveness [101].”
BackgroundKenemans, J. L., & Kähkönen, S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.157 · Cited by 104
“Consistently, acute administration of 16 mg ondansetron, a 5-HT-3 blocker, augmented P50 suppression in typically medicated schizophrenic patients (Adler et al, 2005).”
Smucny, J., Stevens, K. E., Olincy, A., & Tregellas, J. R. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.77 · Cited by 28
Huang, Y., Yoon, K., Ko, H., Jiao, S., Ito, W., Wu, J.-Y., Yung, W.-H., Lu, B., & Morozov, A. (2014) · Cerebral Cortex · doi:10.1093/cercor/bhu209 · Cited by 27
“sion in schizophrenic patients (Adler et al. 2005; Koike et al. 2005).”
Metadata
- Authors
- Adler, L. E., Cawthra, E. M., Donovan, K. A., Harris, J. G., Nagamoto, H. T., Olincy, A., & Waldo, M. C.
- Venue
- American Journal of Psychiatry
- Published
- 2005-02-01
- Volume
- 162
- Issue
- 2
- Pages
- 386-388
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2095162152
- Cited by
- 82
- References
- 0
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.